The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
These findings follow positive Phase 3 results presented earlier this year
First research project, supported by the Gates Foundation, focuses on developing non-hormonal contraceptives for women in low- and middle-income countries
Subscribe To Our Newsletter & Stay Updated
